Anti-ERBB2 (Trastuzumab)-Gly5-modified DM1 ADC

  • 1.00 Dollar US$
  • Published date: November 30, 2017
    • Shirley, New York, United States

https://www.creative-biolabs.com/adc/target-erbb2-37.htm This ADC product is comprised of an anti-ERBB2 monoclonal antibody (Trastuzumab) conjugated via a linker to modified DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation. "Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells."

Result 0 votes
Bella
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Anti-ERBB2-Phor18 molecules ADC

    Anti-ERBB2-Phor18 molecules ADC

    Drug Development Shirley (New York) November 30, 2017 1.00 Dollar US$

    https://www.creative-biolabs.com/adc/target-erbb2-37.htm This ADC product is comprised of an anti-ERBB2 monoclonal antibody conjugated via a Phor18 molecules linker to drug.

  • Anti-ER-a36 (clone SNGmBI)-MB-VC-duocarmycin ADC

    Anti-ER-a36 (clone SNGmBI)-MB-VC-duocarmycin ADC

    Drug Development Shirley (New York) November 30, 2017 1.00 Dollar US$

    https://www.creative-biolabs.com/adc/target-er-a36-36.htm This ADC product is comprised of an anti-ER-a36 monoclonal antibody (clone SNGmB) conjugated via a MB-VC linker to duocarmycin. The duocarmycin is targeted to certain cancers by immunerecognit...

  • Anti-ER-a36 (clone SNGmBI)-SPDB-DM4 ADC

    Anti-ER-a36 (clone SNGmBI)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 30, 2017 1.00 Dollar US$

    https://www.creative-biolabs.com/adc/target-er-a36-36.htm This ADC product is comprised of an anti-ER-a36 monoclonal antibody (clone SNGmB) conjugated via a SPDB linker to DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered...